3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
63
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Recurrence
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Hyperglycemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Endometrial Stromal Tumors
1
Endometrial Hyperplasia
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Alpelisib
2
exemestane
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Metformin
1
Letrozole
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
exemestane
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled